Evidence map›Paper›PMID 40999912›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Model-Guided Systematic Metabolic Engineering for Enhanced Spinosad Biosynthesis in Saccharopolyspora spinosa NHF132.

Shuliu Wang, Yuxin Liu, Qian Zhang, Yue Jiang, Xiaoqian Zeng, Chengyu Zhang, Jiagao Cheng, Weishan Wang, Lixin Zhang, Gao-Yi Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Enhanced spinosad production inSynthetic and systems biotechnology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuliu WangState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Yuxin LiuState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Qian ZhangState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Yue JiangState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Xiaoqian ZengState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Chengyu ZhangState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Jiagao ChengState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Weishan WangState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China.
Lixin ZhangState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.
Gao-Yi TanState Key Laboratory of Bioreactor Engineering (SKLBE), and School of Biotechnology, East China University of Science and Technology (ECUST), Shanghai, 200237, China.ORCID https://orcid.org/0000-0003-2272-0159

Funding

Double World-Class Project-Key Program-Intelligent Biomanufacturing.Focus on Research and Development Plan in Shandong Province 2022CXGC020206Key Research & Development Program of Shandong Province 2022SFGC0104National Natural Science Foundation of China 32121005National Natural Science Foundation of China 32370064Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 24HC2820200the 111 Project B18022
6 · The paper itself

Abstract

Spinosad (a mixture of spinosyns A and D) is a macrocyclic lactone green bioinsecticide produced by Saccharopolyspora spinosa. It is known for its high efficiency, low toxicity, and broad-spectrum activity. Although numerous strategies have been employed to enhance spinosad production, intricate regulation of secondary metabolism and inefficient genetic manipulation impede systematic and comprehensive metabolic engineering in this spinosad-producing strain. In this study, a genome-scale metabolic model (GEM) for Sa. spinosa NHF132 is developed to dissect the intricate secondary metabolic pathways of spinosad biosynthesis, analyzing interactions among precursors, key enzymes, and competing or bypass pathways. Guided by the model, the impact of rhamnose precursor overexpression, gene cluster amplification, short-chain acyl-CoA enhancement, and chassis optimization on spinosad production is systematically evaluated. By integrating these metabolic engineering strategies, engineered strain NHF132-BAC-SP43-NCM achieved a spinosad titer of 1816.8 mg L

Indexed as

MacrolidesMetabolic EngineeringSaccharopolysporaDrug CombinationsDrug CombinationsMacrolidesspinosadgenome‐scale metabolic modelSaccharopolyspora spinosasecondary metabolitespinosadsystems metabolic engineering

Identifiers

PMID40999912
PMCPMC12713090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.